<DOC>
	<DOCNO>NCT01840683</DOCNO>
	<brief_summary>This open-label , single center clinical investigation evaluate efficacy safety Heparin-induced Extracorporeal Lipoprotein Precipitation ( H.E.L.P . ) Therapy treatment non-exudative ( dry ) Age-related Macular Degeneration ( AMD ) . A total 14 clinic visit schedule , one baseline visit , 8 visit H.E.L.P . therapy treatment ( performed period 12 week patient ) 5 follow-up visit perform one week follow 4th H.E.L.P . therapy session 12 week , 24 week , 36 week 52 week final H.E.L.P . therapy session .</brief_summary>
	<brief_title>HELP Therapy Dry AMD</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Diagnosis nonexudative ( dry ) AMD Male female , 50 90 year Presence soft , confluent drusen study eye At least one large ( &gt; 125 Î¼m ) drusen Visual acuity ( VA ) 20/32 20/100 Early treatment Diabetic Retinopathy Study ( ETDRS ) vision Fibrinogen level &gt; 100mg/dL Willing continue lipidlowering medication throughout treatment phase medication take already study Willing continue regular supplemental intake Age relate Eye Disease Study ( AREDS ) vitamins comparable supplement throughout study course Written inform consent Exclusion Criteria ( relate underlie disease ) : Any evidence wet AMD either eye History treatment wet AMD either eye Geographic atrophy involve fovea study eye Fellow eye &lt; 20/400 VA Presence cataract require treatment study Presence glaucoma require new treatment study Presence diabetic vascular retinopathy Previous retinal laser surgical therapy Epiretinal membrane study eye Any ocular condition require therapy study Exclusion Criteria ( General ) : Participation another clinical trial within 30 day Concurrent participation another clinical trial Pregnancy lactation Inability give understand inform consent Inability maintain treatment followup schedule Hypersensitivity fluorescein Test positive infectious status HIV , HBV HCV infection Exclusion Criteria ( H.E.L.P . Apheresis ) : Heparin intolerance Heparin induce thrombocytopenia ( HIT ) II Hemorrhagic diathesis Ulcers gastrointestinal area Hemorrhage Coagulation disorder neoplasm Liver diseases Severe heart failure valvular defect Condition follow apoplexia Dementia During pregnancy lactation C1 esterase inhibitor deficiency hereditary complement component 3 ( C3 ) deficiency</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Age-Related Macular Degeneration ( AMD )</keyword>
	<keyword>Age Related Eye Disease Study ( AREDS )</keyword>
	<keyword>Best-Corrected Visual Acuity ( BCVA )</keyword>
	<keyword>Early Treatment Diabetic Retinopathy Study ( ETDRS )</keyword>
	<keyword>Heparin-Induced Extracorporeal LDL-Cholesterol Precipitation ( HELP )</keyword>
	<keyword>Visual Function Questionnaire ( VFQ )</keyword>
</DOC>